This article is more than 5 years old. Information may no longer be current.
ZanthinNEX astaxanthin to be available in Q4
Click Here to Manage Email Alerts
Valensa Inc. announced last week that ZanthinNEX astaxanthin will be commercially available by the end of 2014.
According to a press release from the company, ZanthinNEX "is a form of the carotenoid astaxanthin produced via a proprietary process using natural enzymatic conversions that delivers a safe finished product that is 'nature equivalent' to conventional astaxanthin produced via extraction from Haematococcus pluvialis."
As a result of this process, Valensa wrote in the release that ZanthinNEX contains the same structure as astaxanthin found in wild salmon and natural algae. The human body will process their product as it would astaxanthin found in an algae-derived product, according to the company.
"Valensa has more than a decade of experience with astaxanthin for the support of human health," Rudi E. Moerck, PhD, CEO and president of Valensa, said in the release. "We have been at the forefront of safe and economical dosage recommendations for this ingredient – where we've actually suggested that lower doses are sufficient and highly effective. ZanthinNEX is the result of our commitment to a scientifically superior, safe and truly nature-equivalent astaxanthin offering.
“The products that we offer our customers should be based on optically active materials, just like in nature,” Moerck continued. “They should be studied for safety, efficacy and bioequivalence and supported by sound science. To do anything less than this goes against our customers’ expectations.”
Bioequivalence and safety testing for ZanthinNEX have been completed, according to Valensa.